Extended Data Fig. 9: Flow cytometric and scRNA-seq profiling of PSC-CM cell dose with insufficient resultant engraftment arrhythmia burden to undergo pre-planned catheter ablation procedure.
(a) Engraftment arrhythmia burden of PSC-CM + CA #2 following cell transplantation. (b) Bar plot depicting proportion of arrhythmogenic SIRPA+CD90−CD200+ and non-arrhythmogenic SIRPA+CD90−CD200- cardiomyocytes for each subject in catheter ablation treatment group. (c) scRNA−seq analysis of cell dose received by PSC-CM + CA #2. (d) Whole-mount cross-section of RA-PSC-CM + CA subject. Engrafted human cardiomyocytes expressed cardiac troponin T (red) and the human-specific anti-nuclear antigen Ku80 (brown). Scarred myocardium, either from percutaneous myocardial infarction or catheter ablation, was identified with aniline blue counterstaining. (e) A small region of surviving human cardiomyocyte graft responsible for residual arrhythmias was identified (high magnification image of boxed region from panel (d)).
